Multiple myeloma patients treated with an experimental CAR-T therapy developed by Bluebird Bio and licensed to Celgene went nearly one year before their cancer progressed, according to updated study results presented Friday night at the annual meeting of the American Society of Clinical Oncology.

The durability of responses to Bluebird’s CAR-T, called BB2121, is a focal point for investors at this year’s ASCO meeting. The exact number — median progression-free survival of 11.8 months — effectively meets the lower end of expectations, which ranged as high as 15 months, based on analyst reports.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I was hoping Adam might put out a piece on mrtx. It currently is the highest short and long term option Vol out there given its high stock price

  • Prolong a dying mothers life by a year
    Adam bashes.
    This vile blogger is a disgrace and karma will not
    Be kind.

    Hopefully one day someone in his family needs a drug to live ONE YEAR MORE

    and that company tells the basher Adam F U

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy